OrganoTherapeutics

OrganoTherapeutics is a biopharmaceutical startup focused on using cutting-edge human-specific midbrain organoids for the discovery and development of effective drug candidates targeting Parkinson’s disease. Established in 2019 and headquartered in Luxembourg, the company has gained attention for its innovative approach in utilizing 3D patient models for drug development. Utilizing its proprietary organoids, OrganoTherapeutics has developed its first own proprietary drug candidates and has access to attractive libraries for further screening.

Notably, the company recently secured Seed Round investment on 26 July 2023 from the KHAN Technology Transfer Fund, signifying endorsement and support for its pioneering work. OrganoTherapeutics' focus on addressing the unmet medical needs in neurodegenerative diseases, particularly Parkinson’s, presents a promising opportunity for investment, potentially contributing to breakthroughs in therapeutics for this prevalent condition.